[
  {
    "variant": "Wild-type",
    "assay": "Protein Interaction Assay",
    "final_evidence_strength": {
      "type": "N/A",
      "strength": "N/A"
    },
    "overall_conclusion": "Functional evidence not applicable as the general class of assay (Protein Interaction Assay) does not effectively model or reflect the disease pathogenesis defined in Step 1."
  },
  {
    "variant": "Alpha-Synuclein A53T",
    "assay": "Protein Aggregation Assay",
    "final_evidence_strength": {
      "type": "Pathogenic",
      "strength": "PS3_very_strong"
    },
    "overall_conclusion": "The Alpha-Synuclein A53T variant showed a significantly increased rate of protein aggregation compared to wild-type and was previously validated in other studies. Multiple replicates were used, and known pathogenic variants were used as controls."
  },
  {
    "variant": "Alpha-Synuclein A30P",
    "assay": "Protein Aggregation Assay",
    "final_evidence_strength": {
      "type": "Benign",
      "strength": "BS3_supporting"
    },
    "overall_conclusion": "The Alpha-Synuclein A30P variant showed a slower rate of protein aggregation compared to wild-type and was previously validated in other studies. Multiple replicates were used, and known benign variants were used as controls."
  }
]